Mutations in the epidermal growth factor receptor (EGFR, also known as ERBB1) that result in resistance to the EGFR inhibitor gefitinib have prompted closer examination of EGFR in patients with non-small-cell lung cancer (NSCLC). Changes in the dimerization partners of EGFR, such as ERBB2 (also known as HER2), or triggering alternative ErbB signalling pathways, such as ERBB3 (also known as HER3),
... [Show full abstract] have a role in gefitinib resistance.